4SC AG to present at the 19th Annual BIO CEO & Investor Conference 2017
Planegg-Martinsried, Germany, 6 February 2017 – 4SC AG (4SC, FSE Prime Standard: VSC) today announced that Dr Jason Loveridge, CEO of 4SC, will present at the 19th Annual BIO CEO & Investor Conference 2017, being held at the Waldorf Astoria Hotel in New York from 13-14 February 2017.
Dr Loveridge‘s presentation will take place on Monday, 13 February 2017 at 4.30 p.m. EST in the Duke of Windsor room during the conference’s Oncology Track. Additionally, he will be available for one-on-one meetings at the conference.
About 4SC
4SC is a clinical-stage biopharmaceutical company dedicated to the development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options for cancer patients that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company’s pipeline comprises promising products that are in various stages of clinical development.
4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 47 employees as of 30 September 2016. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
About BIO CEO & Investor Conference
BIO CEO & Investor Conference is one of the largest annual conferences dedicated to emerging publicly traded as well as private biotech companies. It serves as an investor and networking conference dedicated towards providing an excellent opportunity to biotechnology and life sciences companies to present to, and meet with, institutional investors, analysts and pharmaceutical executives. The conference features plenary sessions, educational sessions, company presentations, and one-on-one meetings.
Forward-looking information
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
The Ruth Group
Dr Robert Flamm, email hidden; JavaScript is required, +1 646 536 7017
MC Services
Katja Arnold, email hidden; JavaScript is required, +49 89 210228-40